Asian Cohort for Alzheimer's Disease (ACAD)
亚洲阿尔茨海默病队列 (ACAD)
基本信息
- 批准号:10555689
- 负责人:
- 金额:$ 832.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvocacyAffectAlzheimer&aposs DiseaseAlzheimer&aposs disease diagnosisAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskAlzheimer’s disease biomarkerAreaAsiaAsianAsian AmericansAsian populationAwarenessBiological MarkersBiologyBloodBlood specimenCanadaCaregiversCategoriesChineseClinicalClinical DataClinical ResearchCognitiveCollaborationsCollectionCommunitiesCommunity HealthCommunity OutreachConsensusDNADataData CollectionData SetDementiaDiagnosisDiagnosticDietDiseaseDrug TargetingEtiologyEuropean ancestryFamilyFrequenciesFundingFutureGeneticGenetic DiseasesGenetic ResearchGenetic studyGenotypeGoldHealth PersonnelHealth care facilityHourHuman GeneticsImmigrationInfrastructureInternationalInvestmentsKnowledgeKoreansLanguageLeadershipLife ExperienceLife StyleLiteratureLong-Term CareMeta-AnalysisMinority GroupsModelingMolecularNeurologicNeurologyParticipantPathway interactionsPatientsPersonsPhysical activityPlasmaPopulationPopulation HeterogeneityProceduresProtocols documentationRecording of previous eventsResearchResearch Project GrantsResourcesRiskRisk FactorsSNP arraySamplingScientistSocioeconomic StatusStagingTrainingTranslatingTranslation ProcessUnited StatesVariantVietnameseadjudicationagedclinical predictorscohortcommunity engagementdata managementdata sharingeffective therapyexperiencefollow-upgene discoverygenetic variantgenome sequencinggenome wide association studygenome-widegeriatric depressionhealth disparityimprovedinsightmetropolitanmulti-ethnicnew therapeutic targetnon-geneticoutreachpolygenic risk scoreprecision medicine clinical trialspreventquality assurancerecruitreference genomerepositoryretention raterisk variantsaliva samplescreeningsexsynergismwhole genome
项目摘要
Overall Abstract
Alzheimer’s disease (AD) affects 5.8 million people in the United States and is an immense burden on our
economy, patients and caregivers. Genome-wide association studies (GWAS) have successfully led to 25
genome-wide significant loci associated with AD risk and many more associations with key clinical covariates.
Most of these findings are made on participants with European ancestry, although efforts to study other
minority populations are taking off. Knowledge about AD genetics among Asian Americans is especially limited
due to lack of participants. Comprising 6% of the US populace, Asian Americans are under-sampled and
deserve more scientific investment.
We propose the Asian Cohort for Alzheimer’s Disease (ACAD), the first large Alzheimer’s Disease (AD)
genetics cohort for Asians in United States (US) and Canada. To address recruitment barriers, we assembled
a team of scientists, clinicians, and community partners with collaborative history and expertise in AD research,
human genetics, and Asian community outreach. We propose to recruit 5,081 participants aged 60 years or
older and of Chinese, Korean, and Vietnamese ancestry from metropolitan areas across US and Canada in
collaboration with community health providers or long-term care facilities that serve Asian communities. We
will collect DNA and plasma biomarkers and use validated, translated data collection forms and
clinical/diagnostic protocols. To support these recruitment and data collection activities, we will form six Cores
that provide administrative oversite, outreach, clinical expertise, data management, biosample management,
and training and quality assurance to support recruitment and analysis activities. All samples will be
genotyped using SNP arrays and imputed using a large Asian-specific reference panel of whole genome
sequencing data from international Asian cohorts. We propose two Research Projects that will analyze genetic,
biomarker and clinical data to investigate impact of lifestyle risk factors, genetic variants for AD risk, evaluate
differential effects of sex and APOE genotypes on AD risk, and predict clinical diagnosis of AD using genetic
and lifestyle risk scores. We will replicate these findings through meta-analysis collaborations with
international Asian cohorts and AD studies from other populations.
总体摘要
阿尔茨海默病(AD)影响美国580万人,是我们国家的巨大负担。
经济、患者和护理人员。全基因组关联研究(GWAS)已成功地导致25个
与AD风险相关的全基因组显著位点以及与关键临床协变量的更多相关性。
大多数这些发现都是对欧洲血统的参与者进行的,尽管研究其他人的努力,
少数民族人口正在增加。亚裔美国人对AD遗传学的了解尤其有限
由于缺乏参与者。亚裔美国人占美国人口的6%,抽样不足,
值得更多的科学投资。
我们提出了阿尔茨海默病亚洲队列(ACAD),第一个大型阿尔茨海默病(AD)
美国(US)和加拿大的亚洲人遗传学队列。为了解决招聘障碍,我们聚集了
一个由科学家、临床医生和社区合作伙伴组成的团队,在AD研究方面具有合作历史和专业知识,
人类遗传学和亚洲社区外展。我们建议招募5,081名60岁或以上的参加者,
来自美国和加拿大大都市地区的中国、韩国和越南血统的老年人,
与社区卫生服务提供者或为亚裔社区服务的长期护理机构合作。我们
将收集DNA和血浆生物标志物,并使用经验证的翻译数据收集表,
临床/诊断协议。为了支持这些招募和数据收集活动,我们将成立六个核心小组,
提供行政管理、外联、临床专业知识、数据管理、生物样本管理,
以及培训和质量保证,以支持征聘和分析活动。所有样品将
使用SNP阵列进行基因分型,并使用全基因组的大型亚洲特异性参考组进行插补
来自国际亚洲队列的测序数据。我们提出了两个研究项目,将分析遗传,
生物标志物和临床数据,以研究生活方式风险因素、遗传变异对AD风险的影响,
性别和APOE基因型对AD风险的不同影响,并使用遗传学方法预测AD的临床诊断
和生活方式风险评分。我们将通过荟萃分析合作复制这些发现,
国际亚洲队列和其他人群的AD研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HELENA Chang CHUI其他文献
HELENA Chang CHUI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HELENA Chang CHUI', 18)}}的其他基金
Quantitative cerebral blood vessel imaging biomarkers for AD and VCID
AD 和 VCID 的定量脑血管成像生物标志物
- 批准号:
10214060 - 财政年份:2021
- 资助金额:
$ 832.6万 - 项目类别:
Quantitative cerebral blood vessel imaging biomarkers for AD and VCID
AD 和 VCID 的定量脑血管成像生物标志物
- 批准号:
10721210 - 财政年份:2021
- 资助金额:
$ 832.6万 - 项目类别:
USC ADRC Diversity Supplement - Guzman
南加州大学 ADRC 多样性补充 - 古兹曼
- 批准号:
10457217 - 财政年份:2020
- 资助金额:
$ 832.6万 - 项目类别:
Asian Cohort for Alzheimer's Disease (ACAD)
亚洲阿尔茨海默病队列 (ACAD)
- 批准号:
10263300 - 财政年份:2020
- 资助金额:
$ 832.6万 - 项目类别:
相似海外基金
Transfer Advocacy Groups: Transforming Culture to Support Community College Transfer Students of Color in Undergraduate Physics
转学倡导团体:转变文化以支持社区学院本科物理有色人种转学生
- 批准号:
2224295 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Continuing Grant
Engaging adolescents for sexual and reproductive health and rights and family planning advocacy in Pakistan.
让巴基斯坦青少年参与性健康和生殖健康及权利以及计划生育宣传。
- 批准号:
490127 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Operating Grants
Developing a network for mutual learning on the potential of creative arts for mental health advocacy and activism in Ghana and Indonesia
建立一个网络,以相互学习创意艺术在加纳和印度尼西亚促进心理健康倡导和行动的潜力
- 批准号:
AH/X009637/1 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Research Grant
Protection without Advocacy: Japan's Failure to Support Persons with Mental Disabilities in the community
没有倡导的保护:日本未能支持社区中的精神残疾人
- 批准号:
23K01937 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Developing a cultural adaptation framework for youth mental health education and advocacy initiatives at Jack.org
Jack.org 为青少年心理健康教育和宣传活动制定文化适应框架
- 批准号:
484618 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Fellowship Programs
8th International RASopathies Symposium: Expanding Research and Care Practice through Global Collaboration and Advocacy
第八届国际 RASopathies 研讨会:通过全球合作和宣传扩大研究和护理实践
- 批准号:
10683644 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Lupus and health information: Evidence-informed advocacy in action
狼疮和健康信息:循证宣传在行动
- 批准号:
485670 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Miscellaneous Programs
Initiating Meaningful Partnerships for Advocacy and Collaborative Training: The IMPACT initiative
发起有意义的倡导和协作培训伙伴关系:IMPACT 倡议
- 批准号:
487847 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Miscellaneous Programs
Creating advocacy and tech to make secondhand first choice.
创造宣传和技术,让二手货成为首选。
- 批准号:
10064859 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Collaborative R&D
Advocacy Strategies supporting Social Determinants of Health: Paving the Path to Community Reintegration and Recovery
支持健康问题社会决定因素的倡导策略:为社区重新融入和恢复铺平道路
- 批准号:
480718 - 财政年份:2023
- 资助金额:
$ 832.6万 - 项目类别:
Miscellaneous Programs